Investigating UV absorption spectrum of paracetamol (5µg/ml, solvent HCl 0.1N) and quinine sulfate (4µg/ml, solvent HCl 0.1N) of antigrip F tablet within the range 200nm to 400nm with HCl 0.1N solution as blank sample showed that: At wavelength 340nm, paracetamol did not absorb, which was not influence to analyze method. The comparison between MCA and normal spectrum method showed that the difference was not statistical significantly α = 0.05 (compared 2 variances, F test, mean values). The advantages of MCA method are rapid, accurate, and solvent-saving. For mixture containing two above ingredients, the content of each formulation’s ingredient can be simultaneous and accurate assayed by measuring absorption level of 4 wavelengths on normal spectrum machine
Spectrophotometry ; Acetaminophen ; Quinine

No abstract available.
Animals ; Babesiosis* ; Clindamycin ; Humans ; Male* ; Quinine

No abstract available.
Animals ; Babesiosis* ; Clindamycin ; Humans ; Male* ; Quinine

An HPLC method for determination of paracetamol and quinin sulfat in Antigrip F tablets is introduced. The chromatographic conditions are follows: Column: Lichrosorb RP18(250 4mm; 5mm); Mobile phase:1.1 g sodium heptanesufonate in L of a mixture of methanol-4% acetic acid-diethylamine(650:350:1);Flow rate:1ml/min;UV detector at 235nm. Experimental results showed that the method is accurate and precise(e=1.16%-1.88%;recoveries 99%-93%)
Acetaminophen ; Quinine ; Chromatography, High Pressure Liquid ; tablets

A case of congenital malaria infection has been studied in a 46-day old female Korean infant. Her mother suffered from malaria infection during pregnancy in Uppervolta, Africa, and returned to Korea at the 9th month of gestation for delivery. At 39 days of age, the clinical features characterized by fever, irritability, pallor, jaundice and hepatosplenomegaly were developed. The laboratory data revealed a hemolytic anemia with thrombocytopenia, hyperbilirubinemia and increased hepatic enzyme values. A peripheral blood smear demonstrated intraerythrocytic malarial parasites snd gametocytes of Plasmodium falcifarum. She was successfully treated with quinine sulfate (25 mg/kg/day in three doses for 5 days) and trimethoprim/sulfamethoxazole (8 mg/kg/day in two doses for 5 days) orally, and repeated blood smear had been negative for malaria. This report also signifies the frst description of congenital malaria in Korea imported from Uppervolta in Africa. A brief review of related literature was made.
parasitology-protozoa ; malaria-congenital ; Plasmodium falciparum ; quinine ; trimethoprim-sulfamethoxazole

BACKGROUND: Nocturnal muscle cramps are sudden, involuntary, painful muscle contractions that occur in the night and are accompanied by hardening of the muscles. Many symptomatic treatments have been introduced for nocturnal muscle cramps, such as quinine, magnesium, and phenytoin. However, the efficacy and safety of these drugs have not been adequately evaluated. To demonstrate the efficacy and safety of phenytoin treatment for nocturnal muscle cramps, we conducted a retrospective study of 16 patients with nocturnal muscle cramps. METHODS: We reviewed 16 patients (6 men, 10 women) who suffered frequent nocturnal muscle cramps and were treated with phenytoin. The patients' clinical information (age, sex, disease duration, and locations of cramps), treatment dosage, and frequency of cramps were obtained by reviewing their medical records. RESULTS: The patients were aged 63.1+/-14.7 years (mean+/-SD; age range, 30-80 years; median age, 68 years). Twelve and four patients received phenytoin doses of 100 and 200 mg/day, respectively. The median duration of medication was 51 days (range, 14-378 days). Phenytoin treatment was effective in all patients; 13 patients (81.3%) experienced a total remission of their symptoms, and a significant reduction (66.7-85.7%) in the frequency of cramps was found in the remaining 3 patients. No adverse effects were reported by any of the patients. CONCLUSIONS: While this retrospective study was conducted with only a small number of patients, the clinical results suggest that phenytoin is a safe and helpful therapy for the treatment of nocturnal muscle cramps.
Drug Therapy ; Humans ; Magnesium ; Male ; Medical Records ; Muscle Contraction ; Muscle Cramp* ; Muscles ; Phenytoin* ; Quinine ; Retrospective Studies

Despite on-going efforts to control malaria, the rate of malaria has not decreased throughout the world. It was believed that endemic malaria had been eradicated in Korea since the end of the 1970s, however it reemerged from 1993 and has been increasing ever since. Besides endemic malaria, imported malaria is also increasing in Korea as the number of overseas travellers and foreign workers increases. We discovered malaria in a two-year-old child who visited Sierra Leone with his missionary father. The patient contracted malaria despite chemo-prophylaxis with chloroquine and was diagnosed as falciparum malaria by blood smear examination and IFAT. He successfully recovered after administraion of quinine and clindamycin without complication. However, the malaria did not respond quickly to chloroqine and Fansidar but a drug resistence test was not performed.
Child* ; Chloroquine ; Clindamycin ; Fathers ; Humans ; Korea ; Malaria* ; Missions and Missionaries ; Quinine ; Sierra Leone

BACKGROUND/AIMS: Bitter taste receptors are expressed throughout the digestive tract. Data on animals have suggested these receptors are involved in the gut hormone release, but no data are available in humans. Our aim is to assess whether bitter agonists influence food intake and gut hormone release in healthy subjects. METHODS: Twenty healthy volunteers were enrolled in a double-blind cross-over study. On 2 different days, each subject randomly received an acid-resistant capsule containing either placebo or 18 mg of hydrochloride (HCl) quinine. After 60 minutes, all subjects were allowed to eat an ad libitum meal until satiated. Plasma samples were obtained during the experiment in order to evaluate cholecystokinin (CCK) and ghrelin levels. Each subject was screened to determine phenylthiocarbamide (PTC) tasting status. RESULTS: Calorie intake was significantly lower when subjects received HCl quinine than placebo (514 +/- 248 vs 596 +/- 286 kcal; P = 0.007). Significantly higher CCK DeltaT90 vs T0 and DeltaT90 vs T60 were found when subjects received HCl quinine than placebo (0.70 +/- 0.69 vs 0.10 +/- 0.86 ng/mL, P = 0.026; 0.92 +/- 0.75 vs 0.50 +/- 0.55 ng/mL, P = 0.033, respectively). PTC tasters ingested a significantly lower amount of calories when they received HCl quinine compared to placebo (526 +/- 275 vs 659 +/- 320 kcal; P = 0.005), whereas no significant differences were found for PTC non-tasters (499 +/- 227 vs 519 +/- 231 kcal; P = 0.525). CONCLUSIONS: This study showed that intra-duodenal release of a bitter compound is able to significantly affect calorie intake and CCK release after a standardized meal. Our results suggest that bitter taste receptor signaling may have a crucial role in the control of food intake.
Animals ; Cholecystokinin* ; Cross-Over Studies ; Eating ; Gastrointestinal Tract ; Ghrelin ; Healthy Volunteers ; Humans ; Meals ; Phenylthiourea ; Plasma ; Quinine*

BACKGROUND/AIMS: Nutrient-induced gut hormone release (eg, cholecystokinin [CCK]) and the modulation of gut motility (particularly pyloric stimulation) contribute to the regulation of acute energy intake. Non-caloric bitter compounds, including quinine, have recently been shown in cell-line and animal studies to stimulate the release of gastrointestinal hormones by activating bitter taste receptors expressed throughout the gastrointestinal tract, and thus, may potentially suppress energy intake without providing additional calories. This study aims to evaluate the effects of intraduodenally administered quinine on antropyloroduodenal pressures, plasma CCK and energy intake. METHODS: Fourteen healthy, lean men (25 ± 5 years; BMI: 22.5 ± 2.0 kg/m²) received on 4 separate occasions, in randomized, double-blind fashion, 60-minute intraduodenal infusions of quinine hydrochloride at doses totaling 37.5 mg (“Q37.5”), 75 mg (“Q75”) or 225 mg (“Q225”), or control (all 300 mOsmol). Antropyloroduodenal pressures (high-resolution manometry), plasma CCK (radioimmunoassay), and appetite perceptions/gastrointestinal symptoms (visual analog questionnaires) were measured. Ad libitum energy intake (buffet-meal) was quantified immediately post-infusion. Oral quinine taste-thresholds were assessed on a separate occasion using 3-alternative forced-choice procedure. RESULTS: All participants detected quinine orally (detection-threshold: 0.19 ± 0.07 mmol/L). Intraduodenal quinine did not affect antral, pyloric or duodenal pressures, plasma CCK (pmol/L [peak]; control: 3.6 ± 0.4, Q37.5: 3.6 ± 0.4, Q75: 3.7 ± 0.3, Q225: 3.9 ± 0.4), appetite perceptions, gastrointestinal symptoms or energy intake (kcal; control: 1088 ± 90, Q37.5: 1057 ± 69, Q75: 1029 ±70, Q225: 1077 ± 88). CONCLUSION: Quinine, administered intraduodenally over 60 minutes, even at moderately high doses, but low infusion rates, does not modulate appetite-related gastrointestinal functions or energy intake.
Animals ; Appetite ; Cholecystokinin ; Energy Intake ; Gastrointestinal Hormones ; Gastrointestinal Tract ; Humans ; Male ; Plasma ; Pylorus ; Quinine

OBJECTIVES: The prevalence of malaria is increasing in recent years and also multidrug resistant malaria is increasing around the world and there is an increasing concern about imported malaria in nonendemic areas. Now many drugs are tried to find out effect on multidrug resistant malaria. We performed this study to investigate the thrapeutic effect of halofantrine in the treatment of chloroquine resistant imported malaria. METHODS: From Feb. 1992 to May 1995, we experienced 35 patients infected with malaria and treated 14 patients among 35 patients with halofantrine. RESULTS: 1) All 14 patients were sailor with a mean age of 39.4 years and infected with malaria. 2) The majority of patients were infected with malaria at Africa. 3) 10 patients were infected with Plasmodium falciparum and the remainder were undetermined. 4) In the 11 cases of chloroquine resistant malaria treated with quinine plus tetracycline combination therapy or Fansidar, 4 cases could not be tolerable due to side effects and resistance to the therapy, we substituted halofantrine for above regimens. 5) In the 10 cases, treated after May 1994, halofantrine was the first choice of treatment because they were the cases of malaria infected in the mid-Africa where the prevalence of chloroquine resistant malaria is high. 6) With halofantrine, all 14 cases were treated with minimal side effects suc4 as nausea, vomiting, anorexia, abdominal pain and fatigue. CONCLUSION: We think halofantrine is a simple and effective regimen against chloroquine resistant malaria and consider this agent as an alternative therapeutic regimen on chloroquine resistant malaria.
Abdominal Pain ; Africa ; Anorexia ; Chloroquine* ; Fatigue ; Humans ; Malaria* ; Military Personnel ; Nausea ; Plasmodium falciparum ; Prevalence ; Quinine ; Tetracycline ; Vomiting